Portfolio Holdings Detail for ISIN IE0009QS7W62
| Stock Name / Fund | MSCI Wld Hlth US A |
| Issuer | |
| Entity holding fund | iShares V Public Limited Company |
| Entity Type | |
| Entity LEI | 549300QETNU1W5JY7Z94 |
| ETF Ticker | WHCA(EUR) Euronext Amsterdam |
Holdings detail for ALNY
| Stock Name | Alnylam Pharmaceuticals Inc |
| Ticker | ALNY(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US02043Q1076 |
| LEI | 529900S3ZI14OWRJII50 |
Show aggregate ALNY holdings
News associated with ALNY
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $315.58 Consensus PT from Brokerages
- Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-one have assigned a buy rating to the […] - 2025-04-18 05:44:49
- Needham & Company LLC Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $320.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of […] - 2025-04-11 06:12:48
- Corebridge Financial Inc. Has $520,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Corebridge Financial Inc. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, HoldingsChannel reports. The fund owned 2,209 shares of the biopharmaceutical company’s stock after selling 50 shares during the quarter. Corebridge Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $520,000 at the end of […] - 2025-04-09 07:44:49
- Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor
- Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), UnitedHealth Group Incorporated (UNH) and Toyota Motor Corporation (TM), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH). - 2025-04-04 20:54:00
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $345.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to $345.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 34.89% from the company’s previous close. A number […] - 2025-04-02 05:27:03
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $342.00 Price Target at Scotiabank
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from $338.00 to $342.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would indicate a potential upside of 33.72% from the company’s previous […] - 2025-04-02 05:26:50
- Incyte Stock: Is INCY Outperforming the Health Care Sector?
- Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects. - 2025-04-01 15:55:45
- Stocks Recover Early Losses and Close Higher as Magnificent Seven Stocks Rebound
- The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. June E-mini S&P futures (ESM25 ) are up +0.08%, and June E-mini Nasdaq futures... - 2025-03-24 12:01:12
- Natixis Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Natixis Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 10,453 shares of the biopharmaceutical company’s stock after acquiring an additional 451 shares during the quarter. Natixis Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $2,460,000 at the […] - 2025-03-24 08:44:53
- Needham & Company LLC Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Needham & Company LLC reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $320.00 price target on the biopharmaceutical company’s stock. A number of other research firms have also recently issued reports on ALNY. William Blair reissued an […] - 2025-03-24 07:00:43
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Citigroup Analyst Says
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective upped by Citigroup from $338.00 to $351.00 in a research note released on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares […] - 2025-03-24 06:24:53
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $390.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the company. Bank of America raised their […] - 2025-03-24 05:48:46
- Royal Bank of Canada Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $330.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to $330.00 in a research report released on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. StockNews.com downgraded shares of Alnylam Pharmaceuticals […] - 2025-03-24 05:48:44
- Stocks Pare Losses as S&P 500 Looks for Weekly Win
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.18%. June E-mini S&P futures (ESM25 ) are down -0.28%, and June E-mini Nasdaq futures... - 2025-03-21 23:21:08
- Weak Corporate Earnings Results Weigh on Stocks
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.81%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.97%. March E-mini S&P futures (ESH25 ) are down -0.84%, and March E-mini Nasdaq futures... - 2025-03-21 20:55:40
- Stocks Fall on Disappointing Corporate Earnings and Economic Worries
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.54%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.62%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.53%. June E-mini S&P futures (ESM25 ) are down -0.50%, and June E-mini Nasdaq futures... - 2025-03-21 18:18:20
- Friday's ETF Movers: XBI, COPX
- In trading on Friday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Alnylam Pharmaceuticals, up about 13.1% and shares of Cytokinetics, up about 7.8% on the day.
And unde - 2025-03-21 16:11:45
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Atria Investments Inc
- Atria Investments Inc increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,311 shares of the biopharmaceutical company’s stock after acquiring an additional 166 shares during the quarter. Atria Investments Inc’s […] - 2025-03-14 09:52:58
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Proficio Capital Partners LLC
- Proficio Capital Partners LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 25,929.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 193,660 shares of the biopharmaceutical company’s stock after acquiring an additional 192,916 shares during the period. Alnylam Pharmaceuticals makes up approximately 0.6% of Proficio Capital Partners […] - 2025-03-14 09:05:23
- USMV's Underlying Holdings Could Mean 11% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-10 11:43:47
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Lessened by Principal Financial Group Inc.
- Principal Financial Group Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,378 shares of the biopharmaceutical company’s stock after selling 230 shares during the quarter. Principal Financial Group Inc.’s holdings […] - 2025-03-06 10:01:07
- New York Life Investment Management LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- New York Life Investment Management LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,384 shares of the biopharmaceutical company’s stock after buying an additional 153 shares during the period. […] - 2025-03-05 10:04:47
- Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $299.48
- Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy […] - 2025-02-27 06:53:09
- Sanctuary Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Sanctuary Advisors LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,915 shares of the biopharmaceutical company’s stock after purchasing an additional 357 shares during the period. Sanctuary […] - 2025-02-26 08:50:51
- Venturi Wealth Management LLC Buys 248 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Venturi Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6,200.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 252 shares of the biopharmaceutical company’s stock after acquiring an additional 248 shares during the […] - 2025-02-25 09:02:56
- Vontobel Holding Ltd. Reduces Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
- Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,804 shares of the biopharmaceutical company’s stock after selling 5,460 shares during the period. Vontobel Holding Ltd.’s […] - 2025-02-21 09:08:50
- Financial Analysis: Alnylam Pharmaceuticals (NASDAQ:ALNY) vs. Mirum Pharmaceuticals (NASDAQ:MIRM)
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Profitability This table compares Alnylam Pharmaceuticals and Mirum […] - 2025-02-21 07:10:51
- Canaccord Genuity Group Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $385.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price raised by Canaccord Genuity Group from $384.00 to $385.00 in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on the company. Barclays increased their […] - 2025-02-19 07:56:18
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a drop of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily volume of 708,000 shares, […] - 2025-02-17 10:22:50
- Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $284.00
- Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the stock. […] - 2025-02-17 09:08:57
MSCI Wld Hlth US A ALNY holdings
| Date | Number of ALNY Shares Held | Base Market Value of ALNY Shares | Local Market Value of ALNY Shares | Change in ALNY Shares Held | Change in ALNY Base Value | Current Price per ALNY Share Held | Previous Price per ALNY Share Held |
|---|
| 2025-04-17 (Thursday) | 2,504 | USD 587,338 | USD 587,338 | | | | |
| 2025-04-16 (Wednesday) | 2,504 | USD 577,172 | USD 577,172 | 0 | USD -1,077 | USD 230.5 | USD 230.93 |
| 2025-04-15 (Tuesday) | 2,504 | USD 578,249 | USD 578,249 | 0 | USD -22,736 | USD 230.93 | USD 240.01 |
| 2025-04-14 (Monday) | 2,504 | USD 600,985 | USD 600,985 | 0 | USD 5,609 | USD 240.01 | USD 237.77 |
| 2025-04-11 (Friday) | 2,504 | USD 595,376 | USD 595,376 | 0 | USD 28,771 | USD 237.77 | USD 226.28 |
| 2025-04-10 (Thursday) | 2,504 | USD 566,605 | USD 566,605 | 0 | USD -42,543 | USD 226.28 | USD 243.27 |
| 2025-04-09 (Wednesday) | 2,504 | USD 609,148 | USD 609,148 | 0 | USD 47,451 | USD 243.27 | USD 224.32 |
| 2025-04-08 (Tuesday) | 2,504 | USD 561,697 | USD 561,697 | 0 | USD -21,610 | USD 224.32 | USD 232.95 |
| 2025-04-07 (Monday) | 2,504 | USD 583,307 | USD 583,307 | 0 | USD -6,986 | USD 232.95 | USD 235.74 |
| 2025-04-04 (Friday) | 2,504 | USD 590,293 | USD 590,293 | 0 | USD -77,849 | USD 235.74 | USD 266.83 |
| 2025-04-02 (Wednesday) | 2,504 | USD 668,142 | USD 668,142 | 0 | USD 27,719 | USD 266.83 | USD 255.76 |
| 2025-04-01 (Tuesday) | 2,504 | USD 640,423 | USD 640,423 | 0 | USD -35,707 | USD 255.76 | USD 270.02 |
| 2025-03-31 (Monday) | 2,504 | USD 676,130 | USD 676,130 | 0 | USD 3,906 | USD 270.02 | USD 268.46 |
| 2025-03-28 (Friday) | 2,504 | USD 672,224 | USD 672,224 | 0 | USD -6,410 | USD 268.46 | USD 271.02 |
| 2025-03-27 (Thursday) | 2,504 | USD 678,634 | USD 678,634 | 0 | USD 4,532 | USD 271.02 | USD 269.21 |
| 2025-03-26 (Wednesday) | 2,504 | USD 674,102 | USD 674,102 | 0 | USD -29,422 | USD 269.21 | USD 280.96 |
| 2025-03-25 (Tuesday) | 2,504 | USD 703,524 | USD 703,524 | 30 | USD -15,668 | USD 280.96 | USD 290.7 |
| 2025-03-24 (Monday) | 2,474 | USD 719,192 | USD 719,192 | 0 | USD 18,209 | USD 290.7 | USD 283.34 |
| 2025-03-21 (Friday) | 2,474 | USD 700,983 | USD 700,983 | 0 | USD 73,725 | USD 283.34 | USD 253.54 |
| 2025-03-20 (Thursday) | 2,474 | USD 627,258 | USD 627,258 | 0 | USD 247 | USD 253.54 | USD 253.44 |
| 2025-03-19 (Wednesday) | 2,474 | USD 627,011 | USD 627,011 | 0 | USD 22,613 | USD 253.44 | USD 244.3 |
| 2025-03-18 (Tuesday) | 2,474 | USD 604,398 | USD 604,398 | 0 | USD -21,796 | USD 244.3 | USD 253.11 |
| 2025-03-17 (Monday) | 2,474 | USD 626,194 | USD 626,194 | 0 | USD 28,080 | USD 253.11 | USD 241.76 |
| 2025-03-14 (Friday) | 2,474 | USD 598,114 | USD 598,114 | 0 | USD 24 | USD 241.76 | USD 241.75 |
| 2025-03-13 (Thursday) | 2,474 | USD 598,090 | USD 598,090 | 0 | USD -1,682 | USD 241.75 | USD 242.43 |
| 2025-03-12 (Wednesday) | 2,474 | USD 599,772 | USD 599,772 | 0 | USD 9,129 | USD 242.43 | USD 238.74 |
| 2025-03-11 (Tuesday) | 2,474 | USD 590,643 | USD 590,643 | 0 | USD 14,028 | USD 238.74 | USD 233.07 |
| 2025-03-10 (Monday) | 2,474 | USD 576,615 | USD 576,615 | 0 | USD -28,327 | USD 233.07 | USD 244.52 |
| 2025-03-07 (Friday) | 2,474 | USD 604,942 | USD 604,942 | -60 | USD -26,607 | USD 244.52 | USD 249.23 |
| 2025-03-05 (Wednesday) | 2,534 | USD 631,549 | USD 631,549 | | | | |
| 2024-11-12 (Tuesday) | 3,235 | USD 870,053 | USD 870,053 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ALNY by for IE0009QS7W62
Show aggregate share trades of ALNY| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-03-25 | BUY | 30 | | | 280.960* | | 251.73 |
| 2025-03-07 | SELL | -60 | | | 244.520* | | 0.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ALNY
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-04-17 | 165,451 | 74 | 243,558 | 67.9% |
| 2025-04-16 | 270,294 | 3,357 | 446,370 | 60.6% |
| 2025-04-15 | 238,076 | 403 | 494,216 | 48.2% |
| 2025-04-14 | 157,148 | 3,912 | 316,108 | 49.7% |
| 2025-04-11 | 486,937 | 14,123 | 679,583 | 71.7% |
| 2025-04-10 | 500,597 | 2,591 | 780,526 | 64.1% |
| 2025-04-09 | 557,115 | 11,336 | 965,760 | 57.7% |
| 2025-04-08 | 214,094 | 1,301 | 383,794 | 55.8% |
| 2025-04-07 | 358,679 | 32,038 | 613,763 | 58.4% |
| 2025-04-04 | 431,556 | 1,025 | 725,195 | 59.5% |
| 2025-04-03 | 342,351 | 477 | 430,262 | 79.6% |
| 2025-04-02 | 233,896 | 1,506 | 378,459 | 61.8% |
| 2025-04-01 | 183,265 | 8,200 | 380,248 | 48.2% |
| 2025-03-31 | 210,777 | 4,770 | 352,191 | 59.8% |
| 2025-03-28 | 133,425 | 181 | 279,765 | 47.7% |
| 2025-03-27 | 203,567 | 6,557 | 375,583 | 54.2% |
| 2025-03-26 | 285,175 | 1,249 | 426,226 | 66.9% |
| 2025-03-25 | 281,688 | 10,979 | 412,440 | 68.3% |
| 2025-03-24 | 482,334 | 25,397 | 826,008 | 58.4% |
| 2025-03-21 | 836,066 | 28,323 | 1,366,248 | 61.2% |
| 2025-03-20 | 192,017 | 151 | 422,450 | 45.5% |
| 2025-03-19 | 179,759 | 63 | 447,452 | 40.2% |
| 2025-03-18 | 180,640 | 478 | 331,282 | 54.5% |
| 2025-03-17 | 121,129 | 153 | 260,376 | 46.5% |
| 2025-03-14 | 105,130 | 8,747 | 179,061 | 58.7% |
| 2025-03-13 | 70,794 | 138 | 132,716 | 53.3% |
| 2025-03-12 | 124,070 | 84 | 268,287 | 46.2% |
| 2025-03-11 | 137,713 | 2,010 | 247,323 | 55.7% |
| 2025-03-10 | 77,724 | 66 | 208,123 | 37.3% |
| 2025-03-07 | 116,885 | 207 | 186,950 | 62.5% |
| 2025-03-06 | 92,455 | 1,888 | 194,307 | 47.6% |
| 2025-03-05 | 95,363 | 2,841 | 215,198 | 44.3% |
| 2025-03-04 | 102,127 | 7,155 | 230,194 | 44.4% |
| 2025-03-03 | 182,302 | 71,207 | 322,456 | 56.5% |
| 2025-02-28 | 159,506 | 37,465 | 349,462 | 45.6% |
| 2025-02-27 | 119,500 | 4,914 | 524,136 | 22.8% |
| 2025-02-26 | 115,646 | 4,038 | 273,587 | 42.3% |
| 2025-02-25 | 265,837 | 13,977 | 605,942 | 43.9% |
| 2025-02-24 | 147,930 | 2,441 | 341,544 | 43.3% |
| 2025-02-21 | 155,104 | 23 | 271,581 | 57.1% |
| 2025-02-20 | 128,867 | 211 | 244,549 | 52.7% |
| 2025-02-19 | 158,043 | 2,371 | 309,938 | 51.0% |
| 2025-02-18 | 119,695 | 66 | 331,019 | 36.2% |
| 2025-02-14 | 144,504 | 12,058 | 250,691 | 57.6% |
| 2025-02-13 | 172,829 | 272 | 275,814 | 62.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.